CAR-T Cell Therapy – 3-part Video Series

CAR-T cell therapy is a personalized, one-time treatment that reprograms a patient's T cells to detect and destroy cancer cells. This therapy could be the last line of treatment for many patients. 

The key steps include:

• Taking white blood cells from the patient.
• Isolating and genetically modifying the patient's T cells to create CAR-T cells.
• Growing billions of CAR-T cells.
• Injecting CAR-T cells back into the patient.
• CAR-T cells tracking down and killing the patient's cancer cells.

CAR-T cells are T cells modified with a Chimeric Antigen Receptor (CAR) to bind to specific proteins on cancer cells. This therapy is highly personalized and involves a complex manufacturing process, making it costly. Effective quality control is crucial to ensure timely product release and patient safety, and bioMérieux provides the necessary expertise and solutions.

Watch the video to learn more about CAR-T cell therapy and its potential:

CAR-T cell therapy is currently indicated for specific types of blood cancer, which affects the production and functioning of blood cells. Blood cancer is the 5th most common type of cancer globally. 

The main types of blood cancer treatable by CAR-T cell therapy include:

• B-cell acute lymphoblastic leukemia, common in children and young adults.
• Diffuse Large B-cell Lymphomas & follicular lymphoma, occurring mainly in adults.
• Multiple Myeloma, most common in older adults.

CAR-T cell therapy is often a last-line treatment for patients who have not responded to standard treatments but is increasingly used as a second-line treatment following chemotherapy. Future research is exploring CAR-T cell therapy for other indications, such as solid tumors, neurological diseases, and infectious diseases.

Discover more about the specific indications for CAR-T cell therapy by watching the video:

Quality control (QC) is essential in the production of CAR-T cell therapies due to the complex manufacturing process and strict quality standards. QC ensures:

• Safety: Absence of bacterial endotoxins or microbial contamination, including mycoplasma.
• Cellular quality attributes: Cell viability, phenotyping, potency, and purity.

QC is critical at every production stage to ensure treatments are effective, safe, and free from contamination, optimize production costs, and accelerate product release. bioMérieux provides automated QC solutions to address these challenges, including:

• 3P® ENTERPRISE: Digitalizes and automates the entire Environmental Monitoring process.
• BIOFIRE®: Next-gen PCR technology for rapid mycoplasma results.
• BACT/ALERT®: Automated microbial detection system for rapid sterility results.
• ENDOLISA®: High-affinity binding recombinant endotoxin detection kit.
• Accellix: Automated flow cytometry tests for cellular quality attributes.

Choosing bioMérieux QC solutions ensures rapid, objective, and accurate results, optimized lab workflows, and timely delivery of safe, reliable treatments to patients.

Watch the video to understand why quality control is critical in CAR-T cell therapy and how bioMérieux solutions can help: